217 related articles for article (PubMed ID: 22367114)
21. [Clinical analysis of recurrence rate and symptom improvement in gastro-esophageal reflux disease patients].
Jeong YJ; Lee DH; Choi TH; Hwang TJ; Lee BH; Nah JC; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Kim N; Jung HC; Song IS
Korean J Gastroenterol; 2010 Feb; 55(2):100-8. PubMed ID: 20168056
[TBL] [Abstract][Full Text] [Related]
22. Proton pump inhibitor after endoscopic resection for esophageal squamous cell cancer: multicenter prospective randomized controlled trial.
Kakushima N; Hori K; Ono H; Horimatsu T; Uedo N; Ohata K; Doyama H; Kaneko K; Oda I; Hikichi T; Kawahara Y; Niimi K; Takaki Y; Mizuno M; Yazumi S; Hosokawa A; Imagawa A; Niimi M; Yoshimura K; Muto M
J Gastroenterol; 2016 Feb; 51(2):104-11. PubMed ID: 25940151
[TBL] [Abstract][Full Text] [Related]
23. Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy.
Roorda AK; Marcus SN; Triadafilopoulos G
Dig Dis Sci; 2011 Oct; 56(10):2871-8. PubMed ID: 21512760
[TBL] [Abstract][Full Text] [Related]
24. GERD assessment including pH metry predicts a high response rate to PPI standard therapy.
Kandulski A; Peitz U; Mönkemüller K; Neumann H; Weigt J; Malfertheiner P
BMC Gastroenterol; 2013 Jan; 13():12. PubMed ID: 23324360
[TBL] [Abstract][Full Text] [Related]
25. Histomorphological differentiation of non-erosive reflux disease and functional heartburn in patients with PPI-refractory heartburn.
Kandulski A; Jechorek D; Caro C; Weigt J; Wex T; Mönkemüller K; Malfertheiner P
Aliment Pharmacol Ther; 2013 Sep; 38(6):643-51. PubMed ID: 23895770
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of salivary pepsin measurement in patients with proton pump inhibitor-refractory gastroesophageal reflux disease symptoms: a prospective comparative study.
Matsumura T; Arai M; Suzuki T; Hoppo T; Seki Y; Kasamatsu S; Ishigami H; Ishikawa K; Okimoto K; Akizue N; Maruoka D; Nakagawa T; Odaka T; Okamoto Y; Kato N
Esophagus; 2020 Jul; 17(3):339-347. PubMed ID: 31982992
[TBL] [Abstract][Full Text] [Related]
27. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
Suzuki T; Matsushima M; Masui A; Tsuda S; Imai J; Nakamura J; Tsukune Y; Uchida T; Yuhara H; Igarashi M; Koike J; Mine T
World J Gastroenterol; 2015 Apr; 21(16):5023-31. PubMed ID: 25945018
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
Miyamoto M; Manabe N; Haruma K
Intern Med; 2010; 49(15):1469-76. PubMed ID: 20686276
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of the PPI test for detection of GERD in Korean patients and factors associated with PPI responsiveness.
Cho YK; Choi MG; Lim CH; Nam KW; Chang JH; Park JM; Lee IS; Kim SW; Choi KY; Chung IS
Scand J Gastroenterol; 2010 May; 45(5):533-9. PubMed ID: 20180645
[TBL] [Abstract][Full Text] [Related]
32. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial.
Terano A; Arakawa T; Sugiyama T; Suzuki H; Joh T; Yoshikawa T; Higuchi K; Haruma K; Murakami K; Kobayashi K;
J Gastroenterol; 2007 Aug; 42(8):690-3. PubMed ID: 17701133
[TBL] [Abstract][Full Text] [Related]
33. The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children.
Lee JH; Kim MJ; Lee JS; Choe YH
Arch Dis Child; 2011 Jan; 96(1):9-13. PubMed ID: 20870626
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection--a randomized controlled study.
Kato T; Araki H; Onogi F; Ibuka T; Sugiyama A; Tomita E; Nagaki M; Moriwaki H
J Gastroenterol; 2010 Mar; 45(3):285-90. PubMed ID: 19957195
[TBL] [Abstract][Full Text] [Related]
35. Role of Reflux in the Pathogenesis of Eosinophilic Esophagitis: Comprehensive Appraisal With Off- and On PPI Impedance-pH Monitoring.
Frazzoni M; Penagini R; Frazzoni L; de Bortoli N; Mauro A; Tolone S; Bertani H; Marsico M; Marocchi M; Marchi S; Conigliaro R; Savarino E
Am J Gastroenterol; 2019 Oct; 114(10):1606-1613. PubMed ID: 31449157
[TBL] [Abstract][Full Text] [Related]
36. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Inadomi JM; McIntyre L; Bernard L; Fendrick AM
Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
[TBL] [Abstract][Full Text] [Related]
37. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
[TBL] [Abstract][Full Text] [Related]
38. Histology of symptomatic gastroesophageal reflux disease: is it predictive of response to proton pump inhibitors?
Miwa H; Takubo K; Shimatani T; Furuta T; Oshima T; Tanaka J; Aida J; Ito M; Kurosawa S; Joh T; Wada T; Habu Y; Watanabe Y; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol Hepatol; 2013 Mar; 28(3):479-87. PubMed ID: 22989221
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of proton pump inhibitor-resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring.
Kawamura O; Hosaka H; Shimoyama Y; Kawada A; Kuribayashi S; Kusano M; Yamada M
Digestion; 2015; 91(1):19-25. PubMed ID: 25632912
[TBL] [Abstract][Full Text] [Related]
40. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
Schey R; Alla SP; Midani D; Parkman HP
Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
